Molly Hemmeter
Analyst · ROTH Capital Partners. Your question, please
Thank you. Good morning and thank you for joining Landec's fourth quarter and fiscal year end 2016 earnings call. With me on the call today is Greg Skinner, Landec's Chief Financial Officer. During today's call, we may make forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially. These risks are outlined in our filings with the Securities and Exchange Commission, including the Company's Form 10-K for fiscal year 2015. Landec's fiscal year 2016 fourth quarter results demonstrate positive momentum in both of our core healthy living businesses. Our Apio food business and our Lifecore bio materials business. Consolidated fourth quarter revenues grew slightly to $135.3 million and gross profit increased 22% to $22.8 million during the fourth quarter of fiscal year 2016 compared to the fourth quarter of last year. Lifecore had an extremely strong fourth quarter, with revenues and gross profit increasing 50% and 86% respectively and operating income increasing a 137% compared to fourth quarter of last year. These fourth quarter results contributed to Lifecore's total fiscal year 2016 achievement that included a record $50.5 million in revenue an increase of 25% and a record $40.1 million in operating income and even more impressive increase of 145%. Our Lifecore business has grown significantly since Landec's acquisition in April 2010. Lifecore's revenues have increased at an annual compounded rate of 16% from $20.3 million to $50.5 million in fiscal year 2016 and EBITDA has increased at an annual compounded rate of 34% from $2.8 million to $16.7 million in fiscal year 2016. Lifecore initially achieved this growth through a relentless pursuit to become the preferred viscoelastic supplier to global ophthalmic market leaders. This premium segment of Hyaluronic Acid or HA market requires medical grade non-animal sourced HA within a highly regulated FDA environment. Lifecore's commitment to working closely with its partners through product formulation technology transfer and regulatory approval has enabled Lifecore to grow its share of this market and expand into future new product opportunities with its customers. More recently, Lifecore's growth has been fueled by a dramatic evolution of it s business model from that of an HA supplier to a fully integrated Contract Development and Manufacturing Organization or CDMO. As a fully integrated CDMO, Lifecore offers expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging of both devices and drugs. Lifecore's unique capabilities and dedication to creating the culture of formal excellence has broadened its appeal to a much wider customer base. The evolution of its business has impacted all aspects of Lifecore including, first Lifecore markets. Lifecore has expanded from the ophthalmic and orthopedic markets to now include oncology and potential markets. Second, Lifecore materials. Lifecore has applied and expanded its capability to include not only viscous HA, but also non-HA materials that are difficult to process. Third, Lifecore products. Lifecore's product offering has broadened from medical devices to include those drugs and devices. Fourth, Lifecore services, Lifecore's capability has significantly expanded from fermentation and filling to include specialty formulation and processing as well as aseptic filling and finished injectable dose form. Lifecore also offers products in both synergies and vials. Finally, Lifecore capacity. Lifecore's demand and capacity has expanded dramatically over the past six-years from manufacturing 1 million syringes per year to 3.5 million syringes per year today with projection of 7 million syringes in the next three-years. As a fully integrated CDMO, Lifecore has broadened its markets, materials, products, services and capacity to grow beyond the HA market. As such, revenues and operating income are expected to continue to grow on average at low double-digits for the foreseeable future. Now turning to Apio. Apio performed as expected during the fourth quarter. The beginning of the quarter was negatively impacted by the last remnants of El Nino, however, even though Apio revenues decreased 4% during the quarter, first half it was essentially flat compared to the fourth quarter of last year and gross margin and our packaged fresh vegetable business increased 50 basis points to 12.2%. With El Nino now behind us, we believe we are well positioned for renewed growth and increase profitability in our food business in fiscal year 2017. We continue to make progress on our long-term strategy of increasing margins and profitability through invitation in our food business. Thus far, we have been successful in this strategy, as we have significantly grown our high margin Eat Smart vegetable and salad revenues at an average annual compounded growth rate of over 80% from $26 million in fiscal year 2013 to $154 million in fiscal year 2016. Our Eat Smart salad products are clearly meeting consumers growing desires to eat healthy, fresh and convenient vegetable products. According to U.S. and Canadian, Nielsen Data for the 52 weeks ended May 28, 2016. The North American retail salad kit market category, which excludes Costco and food service grew 28% in consumer retail dollar, while our Eat Smart salad kits grew 36% in consumer retail dollar showing the same to time period. Eat Smart salads are currently well penetrated in North American club stories and Canadian retail grocery stores. The opportunity to grow Eat Smart salad is twofold. We must increase the number of Eat Smart salad being offered to our existing customers and we must gain new distribution in several major U.S. accounts that currently do not offer our Eat Smart salads. Wal-Mart is one of those accounts. In May of this year, we launched a test in 423 Wal-Mart stores with our Eat Smart's retail salad. Thus far, results have been extremely positive. We are supporting this test with geo targeted online consumer advertising on popular food and health website and social media, as well as through walmart.com. Beginning this week, we are funding in store demos to allow consumers to taste this sweet kale salad during their shopping experience at Wal-Mart. In the past, these demonstrations have proven to drive consumer adoption and we believe we will see similar results in Wal-Mart. In fiscal year 2016, in addition to the products we have made in Apio with these smart salad business and Lifecore’s record year. We have several other successes that significantly contributed to laying the groundwork with future growth in our business. First, we invested over $40 million to expand and equip our Lifecore and Apio facilities to support our growing business segments. Second, our Apio salad business revenues continue to generate growth and creating 18% during fiscal 2016 compared to last year with 27% growth in retail and 11% growth in club. We expect to maintain this momentum through the introduction of several more vegetable salads over the next year. Third, in our food business, we started exploring addition of innovative and convenient new products outside of produce. Particularly in the natural food space through both internal development programs and strategic acquisitions. Fourth, we added new capabilities at Apio and Lifecore by hiring several upper management level employees in the areas of product development , sales and business development. And lastly, Lifecore further deepened its products development pipeline there by creating new business opportunity for [Q2] years to come. Before I discuss the outlook for fiscal year 2017, and our strategic objectives over the next three to five-years, let me turn the call over to Greg for some financial highlights.